NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 150 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 3h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 150 is an oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. Levodopa is converted to dopamine in the brain to restore motor function, while carbidopa blocks premature conversion in the periphery and entacapone extends levodopa availability by inhibiting COMT. The 150 mg strength represents a mid-range dosing option within the STALEVO portfolio.
$0.127MPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Part D utilization (101 claims), indicating limited growth opportunities and potential team downsizing as LOE approaches.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STALEVO 150 currently has zero linked job openings and faces an approaching loss of exclusivity, making it a declining asset with limited career mobility. Professionals assigned to this product should anticipate team restructuring, transition to adjacent Parkinson's therapies, or broader company portfolio reassignment within 1-3 years.
Brand Manager
Worked on STALEVO 150 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.